Vessi Medical

Company Overview

Snapshot

Founded in June 2015 by Eyal Kochavi, Vessi Medical operates with 1–10 employees. The company has raised a total of $18.2 million across two funding rounds from six investors. In February 2024, Vessi Medical closed a Series A round for its innovative cryotherapy bladder cancer treatment.

Business overview

Vessi Medical is developing a novel approach for treating urological tissue, specifically focusing on superficial urological tissue using surface cryotherapy. Their technology employs extreme cold to freeze and destroy abnormal tissue. The Vessi Medical system comprises a stand-alone console and a disposable catheter, designed for insertion into the bladder using existing intravesical techniques. This minimally invasive cryotherapy solution offers a therapeutic alternative to traditional surgery, aiming to reduce costs and complications associated with current treatments. The company operates within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers globally.

Strategic signal

In February 2024, Vessi Medical successfully closed a $16.5 million Series A funding round. This significant capital injection validates the company's innovative cryotherapy approach for bladder cancer treatment and provides crucial resources for advancing its clinical development and market entry. The completion of a first-in-human study with promising results further signals a strong trajectory towards commercialization and potential disruption in urological oncology.

Company Intelligence Q&A

What is Vessi Medical's core technology?

Vessi Medical develops a system for surface cryotherapy, utilizing extreme cold to freeze and destroy abnormal superficial urological tissue, offering a minimally invasive alternative to surgery.

When did Vessi Medical complete its Series A funding round?

In February 2024, Vessi Medical closed its Series A funding round, securing $16.5 million for its cryotherapy bladder cancer treatment. ALIVE Israel Healthtech Fund led this round.

What was the outcome of Vessi Medical's first-in-human study?

Vessi Medical finalized its first-in-human study in 2023, reporting very promising results for its cryotherapy treatment of urological tissue.

What was a key development for Vessi Medical in 2020?

In March 2020, Vessi Medical secured seed funding, with.

What is the primary application of Vessi Medical's technology?

Vessi Medical's technology is primarily applied to the treatment of superficial urological tissue, specifically targeting bladder cancer with its cryotherapy solution.